NCT04771520 2026-03-02
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
M.D. Anderson Cancer Center
Blueprint Medicines Corporation
Blueprint Medicines Corporation
CStone Pharmaceuticals
Blueprint Medicines Corporation